Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.
Chemokine (C-C motif) ligand 17 (CCL17) is a chemokine mainly produced by myeloid dendritic cells. It is a ligand for CC chemokine receptor 4 (CCR4) and CC chemokine receptor 8 (CCR8). The aim of this study was to investigate prognostic values of CCL17 expression in patients with clear cell renal cell carcinoma (ccRCC).



The study included 286 patients with ccRCC. CCL17 expression was analyzed by immunohistochemistry on tissue microarrays. Prognostic values of CCL17 expression and patients' clinical outcomes were evaluated.



Kaplan-Meier method showed that low CCL17 expression was associated with worse patient overall survival (OS) and recurrence-free survival (RFS) (OS, P = 0.002; RFS, P = 0.007). Low CCL17 expression was an adverse independent risk factor for OS and RFS in multivariate analyses (OS, P = 0.006, P = 0.011 for bootstrap; RFS, P = 0.002, P = 0.025 for bootstrap). We constructed two nomograms incorporating parameters derived from multivariate analyses to predict patients' OS and RFS (OS, c-index 0.799; RFS, c-index 0.787) and they performed better than existed integrated models.



Low CCL17 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with ccRCC after nephrectomy. Established nomograms based on this information could help predict ccRCC patients' OS and RFS.
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Ying
Y
Xiong
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Li
L
Liu
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yu
Y
Xia
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jiajun
J
Wang
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Wei
W
Xi
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Qi
Q
Bai
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yang
Y
Qu
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. jjxufdu@fudan.edu.cn.
Jiejie
J
Xu
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. guo.jianming@zs-hospital.sh.cn.
Jianming
J
Guo
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D054414:Chemokine CCL17 / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009392:Nephrectomy; D011379:Prognosis
D014408:Biomarkers, Tumor; C106230:CCL17 protein, human; D054414:Chemokine CCL17
Chemokine (C–C motif) ligand 17; Clear cell renal cell carcinoma; Overall survival; Prognostic factor; Recurrence-free survival